EUSense
Transforming GI Cancer diagnosis and treatment with AI for endoscopic ultrasound
StartupEUSense is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2024. Transforming GI Cancer diagnosis and treatment with AI for endoscopic ultrasound. EUSense was founded by Tamar Rucham and Gal Weisman. The company has 1-10 employees. Core technologies: Artificial Intelligence, Deep Learning, Computer Vision, Image Recognition.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQJerusalem
- DistrictJerusalem District
- Last RoundUndisclosed
Tamar RuchamCEO
Gal WeismanCTO
What does EUSense do?
Endoscopic Ultrasound (EUS) is one of the most advanced GI tools, essential for both diagnosis and minimally invasive procedures such as RFA, localized radiation therapy, and non-surgical drainage. However, its potential is limited by the years of expertise needed to perform these procedures safely and accurately. This makes EUS an ideal candidate for Human-AI collaboration, as it will enable more GI clinics to offer advanced treatments to more patients world-wide. Our patent-pending AI, developed at Clalit, excels at detecting pancreatic abnormalities and shows promising results in malignancy classification. Multiple clinical trial sites are already in place. Our founding team—experts in tech, AI, and clinical care—is driven to make advanced cancer treatments more accessible and effective for patients worldwide.
Who founded EUSense?
EUSense was founded in 2024 by Tamar Rucham (CEO), Gal Weisman (CTO).
What sector is EUSense in?
EUSense operates in Health Tech & Life Sciences, Digital Healthcare, with core technologies in Artificial Intelligence, Deep Learning, Computer Vision, Image Recognition. Target customers: Healthcare & Life Sciences, Healthcare.
Where is EUSense located?
EUSense is based in Jerusalem, Israel, Jerusalem District.